Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Hospitals Say COVID Staff Testing ‘Madness’ Must Be Stopped

Rules prescribing daily hospital COVID testing described as ‘senseless’

Executive Summary

New COVID-19 winter protection rules in Germany, setting a daily testing requirement for hospital staff, represent a potentially massive extra burden for under-pressure providers, says the hospitals federation.

You may also be interested in...



Last-Minute Changes To COVID Law A Good Compromise Says German IVD Industry

Germany’s amended infection prevention law was voted through in the Bundestag after the COVID-19 testing frequency provision for hospital staff was made less onerous. But not everyone is happy.

Climate Compliance For Medtech Businesses: ‘Tactical Changes Are Not Enough’

Health care businesses seeking to reconcile positive climate action with business growth must combine long-term thinking and short-term actions. Only then will they achieve internal and external sustainability goals, says Robert Metzke, Royal Philips’ SVP and global head of sustainability.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel